Type 2 Diabetes – Pipeline Review, H1 2018
- Pages: 1109
- Published: May 2018
- Report Code: GMDHC10467IDB
Global Markets Direct’s, ‘Type 2 Diabetes – Pipeline Review, H1 2018’, provides an overview of the Type 2 Diabetes pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
– The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects
– The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Adocia SAS
Aegis Therapeutics LLC
AFFiRiS AG
Akcea Therapeutics Inc
Allist Shanghai Pharmaceutical Technology Co Ltd
Amarantus Bioscience Holdings Inc
Amgen Inc
Aphios Corp
Arecor Ltd
Arena Pharmaceuticals Inc
AstraZeneca Plc
AusBio Ltd
Avadel Pharmaceuticals Plc
Bayer AG
Betagenon AB
Betta Pharmaceuticals Co Ltd
Biocon Ltd
BioLingus AG
BioRestorative Therapies Inc
Biozeus
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Therapeutics Inc
Braasch Biotech LLC
Bristol-Myers Squibb Co
C4X Discovery Holdings PLC
Cadila Healthcare Ltd
Cadila Pharmaceuticals Ltd
Caelus Health
Cardax Inc
Carmot Therapeutics Inc
Cellix Bio Pvt Ltd
Celon Pharma SA
Center Laboratories Inc
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
Cinnagen Co
CJ HealthCare Corp
CohBar Inc
Concenter BioPharma Silkim Ltd
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dance Biopharm Inc
Delpor Inc
Diabetology (Products) Ltd
Diamyd Medical AB
Diasome Pharmaceuticals Inc
DiscoveryBiomed Inc
DNJ Pharma Inc
Dong-A Socio Holdings Co Ltd
Elcelyx Therapeutics Inc
Eli Lilly and Co
Eloxx Pharmaceuticals Inc
Energenesis Biomedical Co Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Epichem Pty Ltd
Eternygen GmbH
Evotec AG
F. Hoffmann-La Roche Ltd
Generex Biotechnology Corp
Genexine Inc
Genfit SA
Genmedica Therapeutics SL
Genovate Biotechnology Co LTD
Geropharm LLC
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
Hanmi Pharmaceuticals Co Ltd
Heptares Therapeutics Ltd
HitGen LTD
Hyundai Pharmaceutical Co Ltd
Immupharma Plc
Immuron Ltd
Inflazome Ltd
Innovative Targeting Solutions Inc
Inspyr Therapeutics Inc
InStar Technologies AS
Intarcia Therapeutics Inc
Intas Pharmaceuticals Ltd
Integral Molecular Inc
Intercept Pharmaceuticals Inc
Intrexon Corp
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kadimastem Ltd
Kadmon Corp LLC
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
Laboratorios Silanes SA de CV
Lead Discovery Center GmbH
Leading BioSciences Inc
Lexicon Pharmaceuticals Inc
LG Chem Ltd
LipimetiX Development Inc
Longevity Biotech Inc
Luye Pharma Group Ltd
Magnus Life Ltd
MannKind Corp
Medesis Pharma SA
MedImmune LLC
Medlab Clinical Ltd
Merck & Co Inc
Mesoblast Ltd
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
Mitsubishi Chemical Holdings Corp
Mitsubishi Tanabe Pharma Corp
Naia Ltd
Neurimmune Holding AG
NGM Biopharmaceuticals Inc
Novapeutics LLC
Novartis AG
NovaTarg Therapeutics Inc
Novo Nordisk AS
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Original BioMedicals Co Ltd
Palatin Technologies Inc
Panacea Biotec Ltd
Paras Biopharmaceuticals Finland Oy
Peptron Inc
Pfizer Inc
PharmaCyte Biotech Inc
PharmaIN Corp
Pila Pharma AB
Poxel SA
Prometheon Pharma LLC
ProMetic Life Sciences Inc
Prothena Corp Plc
Purzer Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
reMYND NV
Renova Therapeutics Inc
Reset Therapeutics Inc
Rezolute Inc
Saniona AB
Sanofi
Sanwa Kagaku Kenkyusho Co Ltd
SATT Conectus Alsace SAS
SBI Pharmaceuticals Co Ltd
ScandiCure AB
Seres Therapeutics Inc
Serodus ASA
Serometrix LLC
Shenzhen HighTide Biopharmaceutical Ltd
Shionogi & Co Ltd
Sirona Biochem Corp
SJT Molecular Research SL
SK Chemicals Co Ltd
Sprint Bioscience AB
Sumitomo Dainippon Pharma Co Ltd
Suzuken Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Teijin Pharma Ltd
The Medicines Company
Theracos Inc
Thermalin Diabetes LLC
Tiziana Life Sciences Plc
Toray Industries Inc
Torrent Pharmaceuticals Ltd
Transgene Biotek Ltd
TTY Biopharm Company Ltd
Twoxar Inc
Uni-Bio Science Group Ltd
ViaCyte Inc
Vichem Chemie Research Ltd
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
vTv Therapeutics Inc
Vybion Inc
XBiotech Inc
XERIS Pharmaceuticals Inc
XL-protein GmbH
XOMA Corp
XuanZhu Pharma Co Ltd
Yabao Pharmaceutical Group Co Ltd
Yuhan Corp
Zafgen Inc
Zealand Pharma AS
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.